-
Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA), Vertex Pharmaceuticals (VRTX) and Roche Holding AG (OtherRHHVF)
20 Jan 2026 00:24 GMT
… HCA Healthcare (HCA – Research Report), Vertex Pharmaceuticals (VRTX – Research Report) and … 503.00. The company’s shares closed last Friday at $469 … .00. The company’s shares closed last Friday at $441 … CHF320.00. The company’s shares closed last Friday at $ …
-
Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings
20 Nov 2025 00:42 GMT
Vertex Pharmaceuticals Incorporated (VRTX) is a leading … is around $111.3 billion. Shares of the biopharma giant have …
-
What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet?
06 Oct 2025 13:48 GMT
… such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated ( … Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was 1.81%, and its shares … Simons’ Renaissance Technologies? Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) …
-
ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'
03 Oct 2025 13:15 GMT
… partner at Cerity Partners, said Vertex Pharmaceuticals Inc (NASDAQ:VRTX) has … maintained a Buy rating for Vertex Pharmaceuticals on Oct. 2, … .
Price Action:
ServiceNow shares fell 0.3% to … 0.3% on Thursday.
Vertex Pharmaceuticals shares gained 1.2% to …
-
Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Nurix Therapeutics (NRIX)
01 Feb 2026 01:25 GMT
… $45.00. The company’s shares closed last Friday at $25 … $36.00. The company’s shares closed last Friday at $16 … Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and Bristol-Myers Squibb.
Currently …
-
1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals
15 Sep 2025 12:56 GMT
… you to sell this stock.
Shares of Vertex Pharmaceuticals (VRTX -0.63%) have … .
There are 28 analysts following Vertex Pharmaceuticals. None have issued sell ratings … down permanently. Thanks largely to Vertex Pharmaceuticals, a majority of folks born …
-
Agios shares fall on mixed sickle cell results for blood disease drug
20 Nov 2025 00:32 GMT
Dive Brief:
Agios Pharmaceuticals’ anemia pill Pyrukynd missed one of two main goals in a Phase 3 trial in sickle cell disease, failing to significantly reduce the number of pain crises that occur from blood vessel blockages when compared to a placebo, the …
-
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?
19 Nov 2025 22:52 GMT
… a potential takeover has sent shares rallying, as investors bet … , and autoimmune diseases. Its shares are at $53.47 for … gene therapy in partnership with Vertex Pharmaceuticals (VRTX). That landmark was … scarcity tend to drive shares even higher. Buying ahead …
-
Agios readies FDA push in sickle cell disease despite mixed ph. 3 results, shares plummet
19 Nov 2025 22:09 GMT
In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle cell disease (SCD).
Attempting to capture a “broad …
-
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results
06 Aug 2025 04:52 GMT
… , president and CEO of Vertex Pharmaceuticals.
In connection with earnings, … appears to be pressuring shares.
Vertex Pharmaceuticals shares fell 18.8% to trade … to their price targets on Vertex Pharmaceuticals following earnings announcement.
Trending …
About
© 1995-2026